These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26446265)

  • 1. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab.
    López De Padilla CM; Crowson CS; Hein MS; Strausbauch MA; Aggarwal R; Levesque MC; Ascherman DP; Oddis CV; Reed AM
    Clin Exp Rheumatol; 2015; 33(5):655-63. PubMed ID: 26446265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic predictors of clinical improvement in rituximab-treated refractory myositis.
    Reed AM; Crowson CS; Hein M; de Padilla CL; Olazagasti JM; Aggarwal R; Ascherman DP; Levesque MC; Oddis CV;
    BMC Musculoskelet Disord; 2015 Sep; 16():257. PubMed ID: 26382217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
    Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM
    Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
    Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
    Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.
    Zong M; Dorph C; Dastmalchi M; Alexanderson H; Pieper J; Amoudruz P; Barbasso Helmers S; Nennesmo I; Malmström V; Lundberg IE
    Ann Rheum Dis; 2014 May; 73(5):913-20. PubMed ID: 23625983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
    Rider LG; Yip AL; Horkayne-Szakaly I; Volochayev R; Shrader JA; Turner ML; Kong HH; Jain MS; Jansen AV; Oddis CV; Fleisher TA; Miller FW
    Clin Exp Rheumatol; 2014; 32(5):689-96. PubMed ID: 25068290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.
    Nagaraju K; Ghimbovschi S; Rayavarapu S; Phadke A; Rider LG; Hoffman EP; Miller FW
    Rheumatology (Oxford); 2016 Sep; 55(9):1673-80. PubMed ID: 27215813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
    Wong CK; Lam CW; Wu AK; Ip WK; Lee NL; Chan IH; Lit LC; Hui DS; Chan MH; Chung SS; Sung JJ
    Clin Exp Immunol; 2004 Apr; 136(1):95-103. PubMed ID: 15030519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris.
    Timoteo RP; da Silva MV; Miguel CB; Silva DA; Catarino JD; Rodrigues Junior V; Sales-Campos H; Freire Oliveira CJ
    Mediators Inflamm; 2017; 2017():7151285. PubMed ID: 28321152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.
    Torok KS; Kurzinski K; Kelsey C; Yabes J; Magee K; Vallejo AN; Medsger T; Feghali-Bostwick CA
    Semin Arthritis Rheum; 2015 Dec; 45(3):284-93. PubMed ID: 26254121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-C chemokines differentially alter interleukin-4 production from lymphocytes.
    Lukacs NW; Chensue SW; Karpus WJ; Lincoln P; Keefer C; Strieter RM; Kunkel SL
    Am J Pathol; 1997 May; 150(5):1861-8. PubMed ID: 9137108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
    Rosenzwajg M; Languille E; Debiec H; Hygino J; Dahan K; Simon T; Klatzmann D; Ronco P
    Kidney Int; 2017 Jul; 92(1):227-237. PubMed ID: 28318628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection.
    Tiringer K; Treis A; Fucik P; Gona M; Gruber S; Renner S; Dehlink E; Nachbaur E; Horak F; Jaksch P; Döring G; Crameri R; Jung A; Rochat MK; Hörmann M; Spittler A; Klepetko W; Akdis CA; Szépfalusi Z; Frischer T; Eiwegger T
    Am J Respir Crit Care Med; 2013 Mar; 187(6):621-9. PubMed ID: 23306544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Th1/Th2 and macrophage lineage cytokines in leprosy; correlation with circulating CD4(+) CD25(high) FoxP3(+) T-regs cells.
    Abdallah M; Attia EA; Saad AA; El-Khateeb EA; Lotfi RA; Abdallah M; El-Shennawy D
    Exp Dermatol; 2014 Oct; 23(10):742-7. PubMed ID: 25109693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
    Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
    Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses.
    Ghosh TK; Mickelson DJ; Fink J; Solberg JC; Inglefield JR; Hook D; Gupta SK; Gibson S; Alkan SS
    Cell Immunol; 2006 Sep; 243(1):48-57. PubMed ID: 17250816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.
    Stone KB; Oddis CV; Fertig N; Katsumata Y; Lucas M; Vogt M; Domsic R; Ascherman DP
    Arthritis Rheum; 2007 Sep; 56(9):3125-31. PubMed ID: 17763431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.